SABCS 2022 | Remaining challenges regarding HER2-low breast cancer

Antonio Marra, MD, Memorial Sloan Kettering Cancer Center, New York, NY, remaining questions and challenges regarding HER2-low breast cancer, including how new methods to detect HER2-low breast cancer and other tumor types can be validated in a meaningful way. An additional challenge is how to validate the prognostic and predictive role of HER2-low in breast cancer. The majority of studies focus on retrospective analysis, however, prospective studies are required to ascertain the role of HER2-low in breast cancer. This interview took place at the San Antonio Breast Cancer Symposium (SABCS) 2022 in San Antonio, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.